US2013072442A1PendingUtilityA1
Viral Complement Control Proteins for Eye Disorders
Est. expiryOct 8, 2024(expired)· nominal 20-yr term from priority
A61K 9/0051A61K 38/162A61P 27/02A61K 38/17
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compositions and methods for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the compositions comprise a poxvirus complement control protein or a complement binding fragment or variant thereof. Other compositions comprise a poxvirus complement control protein linked to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization, ocular inflammation, or any combination of these. Certain of the methods comprise administering a poxvirus complement control protein or complement binding fragment or variant thereof to a subject.
Claims
exact text as granted — not AI-modified1 . A method of treating an eye disorder characterized by macular degeneration, choroidal neovascularization, retinal neovascularization, or ocular inflammation comprising:
administering an effective amount of a viral complement control protein (VCCP) or viral complement interfering protein (VCIP) or a variant comprising a sequence at least 90% identical to a VCCP or VCIP to a subject in need thereof.
2 . The method of claim 1 , wherein a VCCP is administered.
3 . The method of claim 1 , wherein a VCIP is administered.
4 . The method of claim 1 , wherein the VCCP is a PVCCP or HVCCP.
5 . The method of claim 4 , wherein the PVCCP selected from the group consisting of VCP, SPICE, IMP, and MVPCP.
6 . (canceled)
7 . (canceled)
8 . The method of claim 1 , wherein the VCIP is selected from the group consisting of HSV-1, HSV-2, VZV, PRV, BHV-1, EHV-1, EHV-4, and gC1.
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . The method of claim 1 , wherein the VCCP or VCIP or variant is administered intravenously.
13 . The method of claim 1 , wherein the VCCP or VCIP or variant is locally administered to the eye or in the vicinity of the eye.
14 . The method of claim 13 , wherein the VCCP or VCIP or variant is locally administered in a liquid.
15 . The method of claim 13 , wherein the VCCP or VCIP or variant is locally administered in an ointment or gel.
16 . (canceled)
17 . (canceled)
18 . The method of claim 13 , wherein the VCCP or VCIP or variant is locally administered in an ocular or periocular implant or insert or in a plurality of microparticles or nanoparticles.
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . (canceled)
25 . The method of claim 1 , wherein the subject is at risk of or suffering from age-related macular degeneration (ARMD).
26 . (canceled)
27 . The method of claim 1 , wherein the subject is at risk of or suffering from choroidal neovascularization.
28 . (canceled)
29 . (canceled)
30 . (canceled)
31 . The method of claim 1 , wherein the VCCP or VCIP or variant is administered in a composition that further comprises a moiety that binds to a component present in the eye of a subject at risk of or suffering from the eye disorder.
32 . The method of claim 31 , wherein the moiety binds to a cellular marker present on or at the surface of an endothelial cell or retinal pigment epithelial cell.
33 . The method of claim 31 , wherein the moiety binds to a drusen constituent.
34 . The method of claim 31 , wherein the moiety is linked to the VCCP or VCIP or variant.
35 . A method of inhibiting neovascularization in the eye of a subject in need thereof comprising administering a VCIP or a variant comprising a sequence at least 90% identical to a VCIP to or in close proximity to the posterior segment of the subject's eye.
36 . (canceled)
37 . The method of claim 35 , wherein a VCIP is administered.
38 . (canceled)
39 . (canceled)
40 . (canceled)
41 . (canceled)
42 . (canceled)
43 . The method of claim 35 , wherein the VCIP is selected from the group consisting of HSV-1, HSV-2, VZV, PRV, BHV-1, EHV-1, EHV-4, and gC1.
44 . (canceled)
45 . (canceled)
46 . The method of claim 35 , wherein the VCCP or VCIP or variant is administered as a liquid.
47 . The method of claim 35 , wherein the VCCP or VCIP or variant is administered by a method selected from the group consisting of: retrobulbar injection, peribulbar injection, sub-Tenon injection, subconjunctival injection, and intravitreal injection.
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . The method of claim 35 , wherein the VCCP or VCIP or variant is administered in an ocular or periocular implant or insert or in a plurality of microparticles or nanoparticles.
52 . The method of claim 35 , wherein the VCCP or VCIP or variant is administered in a solution that forms a gel after introduction into the body.
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)
70 . (canceled)
71 . (canceled)
72 . (canceled)
73 . (canceled)
74 . (canceled)
75 . A method of inhibiting ocular inflammation in a subject in need thereof comprising:
administering a VCCP or VCIP or a variant comprising a sequence at least 90% identical to a VCCP or VCIP to the subject.
76 . The method of claim 75 , wherein a VCCP is administered.
77 . (canceled)
78 . (canceled)
79 . (canceled)
80 . (canceled)
81 . (canceled)
82 . (canceled)
83 . (canceled)
84 . (canceled)
85 . (canceled)
86 . (canceled)
87 . (canceled)
88 . (canceled)
89 . (canceled)
90 . (canceled)
91 . (canceled)
92 . (canceled)
93 . (canceled)
94 . (canceled)
95 . (canceled)
96 . (canceled)
97 . A composition comprising a VCCP or VCIP or a variant comprising a sequence at least 90% identical to a VCCP or VCIP and a soluble gel-forming material.
98 . (canceled)
99 . (canceled)
100 . (canceled)
101 . (canceled)
102 . (canceled)
103 . A method of treating an eye disorder characterized by macular degeneration, choroidal neovascularization (CNV), retinal neovascularization (RNV), ocular inflammation, or any combination of these comprising the step of administering the composition of claim 97 to a subject in need thereof.
104 . (canceled)
105 . (canceled)
106 . (canceled)
107 . (canceled)
108 . (canceled)
109 . (canceled)
110 . (canceled)
111 . (canceled)
112 . (canceled)
113 . (canceled)
114 . (canceled)
115 . (canceled)
116 . (canceled)
117 . (canceled)
118 . (canceled)
119 . (canceled)
120 . (canceled)
121 . (canceled)
122 . (canceled)
123 . (canceled)
124 . (canceled)
125 . (canceled)
126 . (canceled)
127 . (canceled)
128 . (canceled
129 . (canceled)
130 . (canceled)
131 . (canceled)
132 . (canceled)
133 . (canceled)
134 . (canceled)
135 . (canceled)
136 . (canceled)
137 . (canceled)
138 . (canceled)
139 . (canceled)
140 . (canceled)
141 . A composition comprising:
(i) a VCCP or VCIP or a variant comprising a sequence at least 90% identical to a VCCP or VCIP; and (ii) a moiety that binds to a component present in the eye of a subject at risk of or suffering from an eye disorder characterized by macular degeneration, CNV, RNV, or ocular inflammation.
142 . The composition of claim 141 , wherein the moiety binds to a cellular marker present on or at the surface of an endothelial cell or retinal pigment epithelial cell.
143 . The composition of claim 141 , wherein the moiety binds to a drusen constituent.
144 . The composition of claim 141 , wherein the moiety is linked to the VCCP or VCIP or variant.
145 .- 170 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.